Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: a MUlticenter Randomized Open-label...

Area of Science:

• Cardiology
• Pharmacology
• Interventional Cardiology

Background:

• Antithrombotic therapy is crucial for ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI).
• High residual platelet reactivity (HRPR) can occur with standard oral antiplatelet loading doses, potentially increasing ischemic risks.
• Alternative strategies are needed to achieve rapid and sustained platelet inhibition, bridging the initial treatment gap.

Purpose of the Study:

• To compare the pharmacodynamic effects of different antiplatelet strategies in STEMI patients undergoing primary PCI.
• To evaluate cangrelor, tirofiban, and different formulations of prasugrel for rapid platelet inhibition.

Main Methods:

• The FABOLUS FASTER trial is a multicentre, open-label, prospective, randomized study.
• It directly compares the pharmacodynamics of intravenous cangrelor, intravenous tirofiban, chewed oral prasugrel, and intact oral prasugrel.
• The study focuses on patients with STEMI undergoing primary PCI.

Main Results:

• This section is to be filled once the study results are available.

Conclusions:

• This study will provide new insights into antiplatelet therapy management for STEMI patients undergoing primary PCI.
• Findings may guide future clinical trials on optimizing antiplatelet strategies to reduce thrombotic events.